1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Southland Holdings received a notice from NYSE American on September 23, 2026, saying it is not in compliance with stockholders' equity listing standards after reporting a $248.2 million stockholders' deficit at June 30, 2026. The shares and warrants remain listed for now, but the company must submit a compliance plan by October 23, 2026, and regain compliance by March 23, 2028, or face delisting proceedings.
NYSE American notice received September 23, 2026, citing Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide
Stockholders' deficit of $248.2 million at June 30, 2026; company reported net losses in its last three fiscal years
Compliance plan due October 23, 2026; compliance deadline March 23, 2028
Shares (SLND) and warrants (SLND WS) continue trading on NYSE American for now
Dyadic International received two Nasdaq deficiency notices on September 25, 2026: one for its stock trading below the $1 minimum bid price for 30 consecutive business days, and one for its market value of listed securities falling below $35 million over the same period. Both notices have no immediate effect on the common stock's listing on the Nasdaq Capital Market, but the company must regain compliance by March 24, 2027 or face delisting notice.
Bid price below $1 per share for the last 30 consecutive business days under Nasdaq Rule 5550(a)(2)
Market value of listed securities below the $35 million minimum for the last 30 consecutive business days under Rule 5550(b)(2)
Compliance Date is March 24, 2027, requiring 10 consecutive business days at or above the thresholds
Company may appeal any delisting determination to a Nasdaq hearings panel, with no assurance of success
Nasdaq notified Fusemachines on September 24, 2026 that its securities are subject to delisting because it did not meet the $50,000,000 minimum market value of listed securities as of September 23, 2026, the deadline for regaining compliance. The company plans to request a hearing before a Nasdaq Hearings Panel, which would pause delisting action, but the filing says there is no assurance the panel will grant continued listing or that the company will regain compliance.
Nasdaq first notified the company on March 27, 2026 that it no longer met the $50,000,000 MVLS requirement
Compliance deadline was September 23, 2026; Nasdaq said the company remained non-compliant as of that date
Company plans to timely request a hearing before the Nasdaq Hearings Panel, which would stay delisting action until the hearing and any panel extension expire
Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, saying it does not meet the $4.0 million stockholders' equity requirement, as it reported $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, and regain compliance by March 21, 2028, or face delisting proceedings, which raises the risk of delisting for shareholders.
Stockholders' equity was $3.1 million as of June 30, 2026, below the $4.0 million NYSE American requires for companies with net losses in three of four recent fiscal years
Notice received September 21, 2026; plan of compliance due October 21, 2026
Company must regain compliance by March 21, 2028; delisting proceedings begin if no plan is submitted or accepted
Common stock continues to trade as CLDI with a ".BC" designation for noncompliance
Future Money Acquisition Corp (Nasdaq: FMAC) received a Nasdaq deficiency letter on September 22, 2026, because it has not yet filed its Form 10-Q for the quarter ended July 31, 2026. The notice has no immediate effect on the listing or trading of the company's securities, but the company must submit a plan to regain compliance by November 23, 2026, and the company says it cannot assure that Nasdaq will accept the plan or grant an exception.
Nasdaq notice dated September 22, 2026, cites Listing Rule 5250(c)(1) on timely periodic reports
Form 10-Q for the fiscal quarter ended July 31, 2026, has not been filed
Company must submit a compliance plan by November 23, 2026
If the plan is accepted, Nasdaq may allow an exception until March 22, 2027
Netcapital Inc. received a Nasdaq notice on September 21, 2026, saying it is not in compliance with the rule requiring timely periodic reports because it has not filed its quarterly report for the period ended July 31, 2026, and remains delinquent on its annual report for the fiscal year ended April 30, 2026. The notice has no immediate effect on the stock, which continues to trade on the Nasdaq Capital Market as NCPL, but the company must submit a compliance plan by October 23, 2026, and there is no assurance Nasdaq will accept it.
Nasdaq notice received September 21, 2026, citing Listing Rule 5250(c)(1)
Company must submit a plan to regain compliance by October 23, 2026
If accepted, Nasdaq may allow an exception until February 9, 2027; if not, the company can appeal to a Nasdaq Hearings Panel
Stock continues to trade on the Nasdaq Capital Market under NCPL for now
SANUWAVE Health received a Nasdaq notice on September 23, 2026, because its Market Value of Listed Securities was below $50 million for 30 consecutive business days, the minimum for continued listing on The Nasdaq Global Market. The notice has no immediate effect on the listing, but if the company does not regain compliance by March 22, 2027, it will receive a delisting notice, and the company cannot guarantee it will keep its listing.
Nasdaq notice received September 23, 2026, citing Listing Rule 5450(b)(2)(A)
Company must close at or above $50 million MVLS for 10 consecutive business days to regain compliance
Compliance period runs 180 calendar days from the notice, until March 22, 2027
Company may consider transferring to The Nasdaq Capital Market if it meets that market's requirements
NextCure filed a petition on September 14, 2026 in the Delaware Court of Chancery asking the court to validate its July 2025 reverse split and the shares issued in reliance on it. The company says a 2026 change to Delaware law creates uncertainty over whether a higher supermajority vote standard should have applied to the 2025 approval, which could affect its pending business combination with Avere Therapeutics and its capitalization. The filing describes the court hearing as the venue where the uncertainty will be addressed.
Petition filed September 14, 2026 under Section 205 of the Delaware General Corporation Law; the court ordered notice to stockholders on September 21, 2026.
The 2025 reverse split amendment received about 89.92% of votes cast and about 64.76% of outstanding shares, short of the 66 2/3% supermajority standard in the charter.
Hearing set for 3:00 p.m. Eastern Time on November 6, 2026 in Wilmington, Delaware.
Stockholders wishing to oppose the petition must file a written submission by October 27, 2026, or appear at the hearing.
GT Biopharma received notice from Nasdaq on September 22, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's common stock maintained a closing bid price above $1.00 for at least ten consecutive business days, which Nasdaq required. The regained compliance removes the risk of delisting that the company had faced under the earlier deadline of November 16, 2026.
Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the minimum bid price requirement.
The stock had closed below $1.00 for 30 consecutive business days, leading to a Nasdaq notice on November 20, 2025.
On May 20, 2026, Nasdaq granted an additional 180 calendar day compliance period, through November 16, 2026.
The company's common stock closed above $1.00 for at least ten consecutive business days to meet the standard.
Nektar Therapeutics disclosed that a federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in their license agreement for rezpegaldesleukin. The jury awarded Nektar $90 million in damages plus interest, to be determined by the court. The verdict remains subject to post-trial proceedings and possible appeal, so the amount Nektar ultimately receives is not yet certain.
Jury verdict returned September 24, 2026 in Nektar Therapeutics v. Eli Lilly & Co., Case No. 3:23-cv-03943-JD
Jury awarded Nektar $90 million in damages plus interest, with interest to be set by the District Court
Verdict is subject to post-trial proceedings and any resulting judgment may be appealed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.